ClinicalTrials.Veeva

Menu

Utilizing Exhaled Breathe Condensate Collection to Study Ion Regulation in Cystic Fibrosis

University of Arizona logo

University of Arizona

Status

Completed

Conditions

Healthy
Cystic Fibrosis

Treatments

Drug: Placebo saline
Drug: Albuterol

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT01880723
1R01HL108962-01 (U.S. NIH Grant/Contract)
08-1123-01

Details and patient eligibility

About

Our aims were to determine if exhaled breath condensate (EBC) could detect differences in ion regulation between cystic fibrosis (CF) and healthy and measure the effect of the albuterol on EBC ions in these populations. We hypothesized EBC chloride and sodium would be lower in CF patients at baseline and that albuterol would decrease EBC sodium and increase EBC chloride.

Enrollment

32 patients

Sex

All

Ages

15 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy subjects:

  • no cardiovascular abnormalities
  • not overweight BMI>25
  • 18-55 years of age

CF subjects:

  • mild to moderate CF (FEV1>40% predicted)
  • clinically diagnosed with positive sweat test (sweat Cl->60mmol/L)
  • 10-55 years of age
  • clinically stable

Exclusion criteria

Healthy subjects will be excluded if:

  • If unable to consent for him/herself (cognitive impairment)
  • Have a history or evidence of cardiovascular and/or pulmonary abnormalities.
  • Have an abnormal 12-lead EKG
  • Have an abnormal pulmonary function test
  • Have a history of asthma
  • Have a history of renal disease or estimated creatinine clearance < 55ml/min
  • Women who are pregnant or planning to become pregnant during the study

CF subjects:

  • If unable to consent for him/herself (cognitive impairment)
  • Physically unable to perform exercise or breathing tests
  • Have a history of renal disease or estimated creatinine clearance < 55ml/min
  • Women who are pregnant or planning to become pregnant during the study.
  • Have an abnormal 12-lead EKG
  • Cystic Fibrosis related diabetes is uncontrolled
  • Forced Expiratory Volume after 1 second (FEV1) is less than 40% predicted
  • Have a history of joint disease
  • Have history of pulmonary exacerbation within the last two weeks
  • Experienced pulmonary hemorrhage within 6 months resulting in greater than 50cc of blood in the sputum
  • not currently enrolled in any other research study

Trial design

Primary purpose

Basic Science

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

32 participants in 2 patient groups, including a placebo group

Albuterol
Experimental group
Description:
2.5 mg diluted in 3mL normal saline nebulized using a Power Neb2 nebulizer
Treatment:
Drug: Albuterol
Saline (healthy only)
Placebo Comparator group
Description:
nebulized 3 ml normal saline using a Power Neb2 nebulizer
Treatment:
Drug: Placebo saline

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems